News - KRAS exon 2 mutation

Frequency of FDA-Approved Companion Diagnostic Biomarkers in Solid Tumors (AMP 2024)

Genomic profiling yields clinically actionable information for approved therapies and evidence of resistance, and it may uncover rational therapeutic opportunities regardless of tumor type.

6 days ago

Tumor mutational burden • Companion diagnostic • BRCA Biomarker • MSi-H Biomarker • BRCA Companion diagnostic • MSi-H Companion diagnostic

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1)

BRAF V600E • KRAS mutation • BRCA2 mutation • TMB-H • MSI-H/dMMR • KRAS G12C • HER-2 negative • PIK3CA mutation • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • RET fusion • ROS1 fusion • KRAS G12 • KRAS exon 2 mutation • ALK-ROS1 fusion

OncoExTra™ test

23d

Treatment Strategies' Impact on Progression-Free Survival According to RMST Function in Metastatic Colorectal Cancer Patients: A Retrospective Study from Romania. (PubMed, J Clin Med)

Consistent with existing literature, our findings showed no survival benefit from locoregional treatments such as surgery of the primary tumor or curative radiotherapy at diagnosis. In contrast, resection of hepatic metastases was associated with improved survival outcomes.

23 days ago

Retrospective data • Journal • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • RAS mutation • KRAS exon 2 mutation

2ms

Frequency of KRAS and BRAF mutations in colorectal carcinoma and their association with clinical-pathological characteristics in a tertiary hospital in Kenya. (PubMed, Front Med (Lausanne))

The patients tend to have a high tumor pathological stage and nodal involvement at diagnosis. The high frequency of KRAS exon 2,3,4 mutation and low frequency of BRAF V600E mutations is similar to what has been reported in literature.

2 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • KIT (KIT proto-oncogene, receptor tyrosine kinase)

BRAF V600E • KRAS mutation • BRAF mutation • BRAF V600 • KIT mutation • KRAS exon 2 mutation

2ms

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)

P2, N=18, Active, not recruiting, David E Gerber | Recruiting --> Active, not recruiting | N=34 --> 18

2 months ago

Enrollment closed • Enrollment change

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)

KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation

denifanstat (TVB-2640)

2ms

Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report. (PubMed, World J Clin Cases)

Sotorasib has shown promising clinical efficacy in patients with the KRAS G12c mutation and has no apparent toxic side effects.

2 months ago

Journal • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12C • KRAS G12 • KRAS exon 2 mutation

Lumakras (sotorasib)

7ms

Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients. (PubMed, J Gastrointest Cancer)

The study's findings indicate a rising frequency of mutations in these genes in Iran, highlighting the need to screening mutations in the main exons of all three genes for effective colorectal cancer treatment strategies.

7 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

KRAS mutation • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS Q61 • KRAS Q61H • KRAS exon 2 mutation • NRAS G12D • BRAF amplification • BRAF exon 15 mutation

7ms

Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis. (PubMed, Target Oncol)

Our data demonstrate that RAS mutations do not affect outcome in rego-treated patients as well as TFD/TPI-treated patients. Nevertheless, a trend toward a higher efficacy of rego in RAS-mutated (in particular codon 12, rare RAS mutations, and G12D) patients has been recorded. The rego-TFD/TPI sequence seems to be superior to the reverse sequence in patients carrying an RAS codon 12 mutation, although the impact of other factors as disease burden or performance status cannot be excluded.

7 months ago

Retrospective data • Journal • Metastases

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS wild-type • RAS mutation • RAS wild-type • KRAS G12 • KRAS exon 2 mutation • NRAS G12D • NRAS G12

Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)

7ms

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (clinicaltrials.gov)

P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: Feb 2024 --> Jul 2024

7 months ago

Trial completion date • Combination therapy • Metastases

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

futuximab/modotuximab (S95026) • S95029 • Sym021

8ms

Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases (PubMed, Zhonghua Bing Li Xue Za Zhi)

Accurate pathological diagnosis is prognostically valuable. The histological features of enteroblastic differentiation, elevated serum AFP levels, and the expression of oncofetal proteins play an important role in the tumor diagnosis.

8 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4)

KRAS mutation • KRAS wild-type • KRAS G13 • KRAS exon 2 mutation • NRAS G13 • KRAS exon 2 wild-type

8ms

Primary Rosai-Dorfman disease of the central nervous system: A clinical, histological, and molecular appraisal. (PubMed, Neuropathology)

Nuclear Cyclin D1 expression along with S-100 positivity in the tumor cells is a strong diagnostic clue. BRAF and KRAS mutations are rare in CNS RDD.

8 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • CCND1 (Cyclin D1) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule) • GFAP (Glial Fibrillary Acidic Protein)

BRAF V600E • KRAS mutation • BRAF V600 • KRAS exon 2 mutation • CCND1 expression • KRAS expression

8ms

DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature. (PubMed, Lab Med)

We observed 7 DNA copy number aberrations (CNAs) in primary and metastatic tumor specimens; an additional 7 CNAs were exclusively detected in the metastatic tumor specimens. These DNA alterations may be genetic drivers in the pathogenesis of the tumor specimen from our patient and may serve as biomarkers for the classification and prognosis of NSCLC.

8 months ago

Review • Journal • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS G12D • KRAS G12 • KRAS exon 2 mutation

8ms

External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium. (PubMed, Clin Chem)

Divergent (pre)analytical protocols could lead to discrepant clinical outcomes when using the same plasma samples. Standardization of (pre)analytical work flows can facilitate the implementation of reproducible liquid biopsy testing in the clinical routine.

8 months ago

Journal • Circulating tumor DNA

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • KRAS G12C • KRAS G12 • KRAS exon 2 mutation • EGFR S752_I759del • BRAF exon 15 mutation

9ms

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (clinicaltrials.gov)

P1/2, N=68, Completed, Cardiff Oncology | Active, not recruiting --> Completed

9 months ago

Trial completion

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • BRAF mutation • KRAS exon 2 mutation

Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)

9ms

Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines. (PubMed, Genes (Basel))

The anti-tumor effects of LY3009120 were observed in nine melanoma cell lines, indicating the potential feasibility of experimental trials with LY3009120. The present study reveals that the irradiation-resistant canine metastasis cells (cRGO1.2) harboring the NRAS p.G13R mutation are significantly LY3009120-sensitive, while the equine metastases-derived eRGO6 cells show significant resistance to LY3009120, which make them both valuable tools for studying resistance mechanisms in comparative oncology.

9 months ago

Preclinical • Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

KRAS mutation • BRAF mutation • NRAS mutation • KIT exon 11 mutation • NRAS Q61 • KRAS Q61H • KRAS exon 2 mutation • NRAS G13 • NRAS G13R • BRAF exon 11 mutation • BRAF exon 15 mutation

LY3009120

9ms

AB122 Platform Study (clinicaltrials.gov)

P1, N=715, Recruiting, Taiho Pharmaceutical Co., Ltd. | N=367 --> 715 | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026

9 months ago

Enrollment change • Trial completion date • Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)

KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation

Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)

9ms

P1, N=51, Active, not recruiting, Institut de Recherches Internationales Servier | Recruiting --> Active, not recruiting

9 months ago

Enrollment closed

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

futuximab/modotuximab (S95026) • S95029 • Sym021

10ms

Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lung and its associated lung cancer in adults (PubMed, Zhonghua Bing Li Xue Za Zhi)

CCAM of the lung is a congenital disease, and in adults, type 1 is most commonly found in the pathological classification, and it is often accompanied by cancer. Gene mutations are frequently detected in CCAM of the lung, KRAS being the most recurrent mutation which may play an important role in the carcinogenesis.

10 months ago

Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • KRAS exon 2 mutation

10ms

Association of Orai1 and Peizo1 genes expression with cellular proliferation, metastasis and angiogenesis biomarkers in colon tumor biopsies of CRC patients. (PubMed, Cell Mol Biol (Noisy-le-grand))

Notably, mutant KRAS exon 2 samples exhibit elevated CCL3 and VEGFA expression, suggesting a nuanced link between specific KRAS mutations and the tumor microenvironment. These findings illuminate the intricate molecular landscape of colon cancer and emphasize the potential roles of calcium channels, angiogenesis-related genes, and oncogenic mutations as prognostic markers and therapeutic targets.

10 months ago

Journal • Biopsy

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • CCL3 (C-C Motif Chemokine Ligand 3)

KRAS mutation • BRAF mutation • VEGFA elevation • KRAS exon 2 mutation • VEGFA expression

10ms

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience. (PubMed, Oncol Ther)

Optimized technical workflows are crucial in the decision-making strategy of patients with NSCLC. Artificial reference specimens enable optimization of diagnostic workflows for predictive molecular analysis in routine clinical practice.

10 months ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • KRAS G12C • MET exon 14 mutation • ROS1 fusion • KRAS G12 • KRAS exon 2 mutation • EGFR E746

11ms

FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov)

P3, N=673, Active, not recruiting, Ludwig-Maximilians - University of Munich

11 months ago

Trial completion date • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium

11ms

CR-SEQUENCE: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (clinicaltrials.gov)

P3, N=419, Active, not recruiting, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Trial primary completion date: Jun 2024 --> Jun 2025

11 months ago

Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)

KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium

11ms

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov)

P2, N=59, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025

11 months ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1)

KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • EGFR S492R • KRAS exon 2 wild-type

Mekinist (trametinib) • Vectibix (panitumumab)

11ms

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas (clinicaltrials.gov)

P2, N=34, Recruiting, David E Gerber | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2024

11 months ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)

KRAS mutation • EGFR mutation • ALK rearrangement • KRAS exon 2 mutation • KRAS exon 12 mutation

denifanstat (TVB-2640)

12ms

P1, N=41, Recruiting, Institut de Recherches Internationales Servier | Phase classification: P1a/1b --> P1

12 months ago

Phase classification • Combination therapy • Metastases

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

futuximab/modotuximab (S95026) • S95029 • Sym021

12ms

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer. (PubMed, Biomed Rep)

KRAS wild-type patient resistance may be related to PIK3CA gene mutations, although this needs further verification in larger cohorts. BRAF mutations may be associated with RNF215 expression in patients with CRC.

12 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF mutation • NRAS mutation • PIK3CA mutation • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • PIK3CA expression • PIK3CA wild-type

12ms

Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R. (PubMed, Anticancer Drugs)

In the third-line course, the patient also did not respond to the combination treatment of furaquitinib and cindilimab. The patient died 8 months after treatment initiation. In this study, we found amplification of the rare oncogenic KRASP34R was not only associated with an aggressive phenotype, but also supported cancer resistance to cetuximab, chemotherapy, and immunotherapy.

12 months ago

Journal • IO biomarker • Metastases

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)

KRAS exon 2 mutation

Erbitux (cetuximab) • Tyvyt (sintilimab)

12ms

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (clinicaltrials.gov)

P1/2, N=68, Active, not recruiting, Cardiff Oncology | Phase classification: P1b/2 --> P1/2

12 months ago

Phase classification

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • BRAF mutation • KRAS exon 2 mutation

Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)

1year

FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov)

P3, N=673, Active, not recruiting, Ludwig-Maximilians - University of Munich | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Nov 2023

1 year ago

Enrollment closed • Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase)

KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • irinotecan • leucovorin calcium

1year

AIO-KRK-0116: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (clinicaltrials.gov)

P2, N=109, Active, not recruiting, Ludwig-Maximilians - University of Munich | Trial primary completion date: Nov 2022 --> Nov 2023

1 year ago

Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium

1year

FIRE-6: FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC (clinicaltrials.gov)

P2, N=57, Active, not recruiting, Ludwig-Maximilians - University of Munich | Trial primary completion date: Aug 2022 --> Nov 2023

1 year ago

Trial primary completion date

KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)

KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Erbitux (cetuximab) • 5-fluorouracil • Bavencio (avelumab) • irinotecan • leucovorin calcium

1year

Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review. (PubMed, Diagn Pathol)

We report here for the first time an extraordinarily rare case of synchronous renal tumors of a PRNRP and UC in the ipsilateral kidney of an RTR. We identified simultaneous KRAS, FGFR3, and KDM6A mutations in two different renal masses in the ipsilateral kidney. Pathologic assessment with comparative molecular analysis of mutational profiles facilitates tumor studies after RT and may be of great value in clinical management strategies.

1 year ago

Review • Journal

KRAS (KRAS proto-oncogene GTPase) • FGFR3 (Fibroblast growth factor receptor 3) • KDM6A (Lysine Demethylase 6A)

KRAS mutation • KRAS G12D • FGFR3 mutation • FGFR3 S249C • KRAS G12 • KRAS exon 2 mutation • KDM6A mutation

1year

Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation. (PubMed, Turk J Gastroenterol)

It is necessary to have a comprehensive database of genomic alterations of colorectal carcinomas to interpret mutations more accurately clinically. There are no studies on the frequency of mutations in colorectal carcinomas in the Turkish population; thus, follow-up and treatment protocols are organized following the European and American databases and guidelines. A comprehensive study of the colorectal carcinoma patients' mutation profile in the Turkish patient cohort by the next-generation sequencing method will help to provide significant therapeutic, prognostic, and predictive data and design more successful treatment and follow-up strategies.

1 year ago

Journal • Next-generation sequencing • BRCA Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • MSH3 (MutS Homolog 3) • CDC27 (Cell Division Cycle 27)

KRAS mutation • BRAF mutation • PIK3CA mutation • KRAS exon 2 mutation

1year

Characterizing Intraprimary Tumor Genetic Heterogeneity in Colorectal Carcinoma with Multiple Driver Alterations (AMP 2023)

These data support that the tumor likely arose from three separate clonal populations, the BRAF V600E population and the KRAS G12G and KRAS G12C populations, each having distinct molecular pathways to tumorigenesis. Future directions include measuring spatial gene expression patterns of the tumor to correlate with the tumor mapping described above and to further characterize the multiple populations of tumor cells harboring different driver alterations and molecular pathways to tumorigenesis.

1 year ago

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)

BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • KRAS G12D • BRAF V600K • KRAS G12 • KRAS exon 2 mutation • NRAS G12D • HRAS G12C • BRAF V600E + KRAS G12D

Cologuard®

1year

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer. (PubMed, Curr Issues Mol Biol)

NRAS and BRAF mutations were significantly more frequent in the right colon. BRAF mutation was more common in women and in the right colon.

1 year ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)

BRAF V600E • KRAS mutation • BRAF mutation • NRAS mutation • KRAS G12D • RAS mutation • KRAS G12 • KRAS exon 2 mutation • NRAS G12D • KRAS exon 3 mutation • KRAS exon 4 mutation

1year

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer. (PubMed, Int J Gen Med)

KRAS/NRAS mutations are associated with distant metastasis and BRAF/PIK3CA mutations are associated with poor tumor differentiation in CRC. And the results provided a better understanding between clinicopathological characteristics and gene mutations in CRC patients.

1 year ago

Journal

KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • KRAS exon 2 mutation

1year

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease (clinicaltrials.gov)

P2, N=1, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to low accrual

1 year ago

Trial termination

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • SRSF2 (Serine and arginine rich splicing factor 2) • WT1 (WT1 Transcription Factor) • CSF3R (Colony Stimulating Factor 3 Receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)

DNMT3A mutation • ASXL1 mutation • TET2 mutation • FLT3 D835 • U2AF1 mutation • KRAS exon 2 mutation • FLT3 D835H • IDH1 R132

Vyxeos (cytarabine/daunorubicin liposomal formulation)

1year

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania. (PubMed, Int J Mol Sci)

It provides novel insights into genetic variations specific to the population from Northeastern Romania, which has been underrepresented in previous studies within Eastern Europe. Furthermore, our findings enable the development of genetic profiles in a developing country with limited access to specialized genetic tests and facilitate comparisons with other populations.

1 year ago

Journal • Metastases

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)

TP53 mutation • KRAS mutation • BRAF mutation • PIK3CA mutation • TP53 wild-type • KRAS wild-type • RAS mutation • KRAS exon 2 mutation • KRAS exon 3 mutation

1year

Different prognostic values of KRAS exon 2 sub-mutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of 7 trials. (PubMed, Ann Oncol)

Testing for both RAS and BRAF mutations in stage III patients should be considered as they can better define individual patient prognosis, and may also enable patient selection for (neo)adjuvant trials dedicated to specific poor prognosis molecular subtypes.

1 year ago

Retrospective data • Journal • MSi-H Biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • RAS (Rat Sarcoma Virus)

BRAF V600E • KRAS mutation • MSI-H/dMMR • KRAS G12C • BRAF mutation • BRAF V600 • KRAS G12D • RAS mutation • KRAS G12 • KRAS exon 2 mutation

1year

Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications. (PubMed, BMJ Case Rep)

She had an aggressive clinical course following initiation of cytarabine-based induction chemotherapy. The underlying mutational landscape may significantly influence the biological behaviour of otherwise favourable risk of CBF-AML cases.

1 year ago

Journal

KRAS (KRAS proto-oncogene GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CBFB (Core-Binding Factor Subunit Beta 2)

KRAS mutation • KRAS exon 2 mutation • KIT exon 17 mutation • CBFB-MYH11 fusion

cytarabine

over1year

OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (clinicaltrials.gov)

P3, N=348, Recruiting, Federation Francophone de Cancerologie Digestive | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Sep 2023 --> Sep 2025

over 1 year ago

Trial completion date • Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)

KRAS mutation • NRAS mutation • RAS mutation • KRAS exon 2 mutation

Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium

over1year

P3, N=419, Active, not recruiting, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Trial primary completion date: Jun 2023 --> Jun 2024

over 1 year ago

Trial primary completion date • Metastases

KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)

KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium

over1year

P1a/1b, N=39, Recruiting, Institut de Recherches Internationales Servier | N=129 --> 39 | Trial completion date: Jul 2025 --> Jan 2024 | Trial primary completion date: May 2023 --> Jan 2024

over 1 year ago

Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type

futuximab/modotuximab (S95026) • S95029 • Sym021